Delcath Systems delivered a strong second quarter in 2025, with total revenue more than tripling year-over-year, driven primarily by robust HEPZATO KIT sales. The company achieved net income and positive adjusted EBITDA, a significant turnaround from losses in the prior year, and reported a healthy cash position.
Total revenue surged to $24.2 million, a substantial increase from $7.8 million in Q2 2024, primarily due to strong HEPZATO KIT sales.
The company reported a net income of $2.7 million, a significant improvement from a net loss of $13.7 million in the same period last year.
Non-GAAP adjusted EBITDA turned positive at $9.8 million, compared to a loss of $0.8 million in Q2 2024, indicating improved operational efficiency.
Cash provided by operations was $7.3 million, and the company held $81.0 million in cash and investments with no debt as of June 30, 2025.
Delcath Systems updated its full-year 2025 financial guidance, projecting significant revenue growth and continued positive adjusted EBITDA and cash flow.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance